RESUMEN
Estimation of xenobiotic kinetics in humans frequently relies upon extrapolation from experimental data generated in animals. In an accompanying paper, we have presented a unique, generic, physiologically based pharmacokinetic model and described its application to the prediction of rat plasma pharmacokinetics from in vitro data alone. Here we demonstrate the application of the same model, parameterized for human physiology, to the estimation of plasma pharmacokinetics in humans and report a comparative evaluation against some recently published predictive methods that involve scaling from in vivo animal data. The model was parameterized through an optimization process, using a training set of in vivo data taken from the literature, and validated using a separate test set of published in vivo data. On average, the vertical divergence of the predicted plasma concentrations from the observed data, on a semilog concentration-time plot, was 0.47 log unit. For the training set, more than 80% of the predicted values of a standardized measure of the area under the concentration-time curve were within 3-fold of the observed values; over 70% of the test set predictions were within the same margin. Furthermore, in terms of predicting human clearance for the test set, the model was found to match or exceed the performance of three published interspecies scaling methods, all of which showed a distinct bias toward overprediction. We conclude that the generic physiologically based pharmacokinetic model, as a means of integrating readily determined in vitro and/or in silico data, is potentially a powerful, cost-effective tool for predicting human xenobiotic kinetics in drug discovery and risk assessment.
Asunto(s)
Modelos Biológicos , Xenobióticos/sangre , Xenobióticos/farmacocinética , Acecainida/sangre , Acecainida/farmacocinética , Animales , Área Bajo la Curva , Biperideno/sangre , Biperideno/farmacocinética , Dexametasona/sangre , Dexametasona/farmacocinética , Humanos , Inyecciones Intravenosas , Tasa de Depuración Metabólica , Modelos Animales , Reproducibilidad de los Resultados , Especificidad de la Especie , Factores de Tiempo , Verapamilo/sangre , Verapamilo/farmacocinética , Xenobióticos/administración & dosificaciónRESUMEN
The routine assessment of xenobiotic in vivo kinetic behavior is currently dependent upon data obtained through animal experimentation, although in vitro surrogates for determining key absorption, distribution, metabolism, and elimination properties are available. Here we present a unique, generic, physiologically based pharmacokinetic (PBPK) model and demonstrate its application to the estimation of rat plasma pharmacokinetics, following intravenous dosing, from in vitro data alone. The model was parameterized through an optimization process, using a training set of in vivo data taken from the literature and validated using a separate test set of in vivo discovery compound data. On average, the vertical divergence of the predicted plasma concentrations from the observed data, on a semilog concentration-time plot, was approximately 0.5 log unit. Around 70% of all the predicted values of a standardized measure of area under the concentration-time curve (AUC) were within 3-fold of the observed values, as were over 90% of the training set t1/2 predictions and 60% of those for the test set; however, there was a tendency to overpredict t1/2 for the test set compounds. The capability of the model to rank compounds according to a given criterion was also assessed: of the 25% of the test set compounds ranked by the model as having the largest values for AUC, 61% were correctly identified. These validation results lead us to conclude that the generic PBPK model is potentially a powerful and cost-effective tool for predicting the mammalian pharmacokinetics of a wide range of organic compounds, from readily available in vitro inputs only.
Asunto(s)
Modelos Biológicos , Xenobióticos/sangre , Xenobióticos/farmacocinética , Algoritmos , Animales , Área Bajo la Curva , Clozapina/sangre , Clozapina/farmacocinética , Eritromicina/sangre , Eritromicina/farmacocinética , Semivida , Inyecciones Intravenosas , Tasa de Depuración Metabólica , Modelos Animales , Análisis Multivariante , Pentazocina/sangre , Pentazocina/farmacocinética , Fenitoína/sangre , Fenitoína/farmacocinética , Ratas , Reproducibilidad de los Resultados , Factores de Tiempo , Xenobióticos/administración & dosificaciónRESUMEN
Although epidermal growth factor (EGF) induces transient activation of Ras and the mitogen-activated protein kinase (MAPK) cascade in PC12 cells, whereas nerve growth factor (NGF) stimulates sustained activation, the basis for these contrasting responses is not known. We have developed a computer simulation of EGF-induced MAPK cascade activation, which provides quantitative evidence that feedback inhibition of the MAPK cascade is the most important factor in determining the duration of cascade activation. Hence, we propose that the observed quantitative differences in EGF and NGF signalling can be accounted for by differential feedback regulation of the MAPK cascade.